Differences in Perceived Threat and Efficacy in Managing Opioid Use Disorder versus Alcohol Use Disorder

References

• Abraham, A. J., Andrews, C. M., Yingling, M. E., & Shannon, J. (2018). Geographic disparities in availability of opioid use disorder treatment for medicaid enrollees. Health Services Research, 53(1), 389–404. https://doi.org/10.1111/1475-6773.12686
   PubMed Web of Science ®Google Scholar
• Ali, M. M., Teich, J. L., & Mutter, R. (2017). Reasons for not seeking substance use disorder treatment: Variations by health insurance coverage. The Journal of Behavioral Health Services & Research, 44(1), 63–74. https://doi.org/10.1007/s11414-016-9538-3
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. (5th ed.).
   Google Scholar
• Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine (Malden, Mass.), 12(4), 657–667. https://doi.org/10.1111/j.1526-4637.2011.01075.x
   PubMed Web of Science ®Google Scholar
• Bogdanowicz, K. M., Stewart, R., Broadbent, M., Hatch, S. L., Hotopf, M., Strang, J., & Hayes, R. D. (2015). Double trouble: Psychiatric comorbidity and opioid addiction—All-cause and cause-specific mortality. Drug and Alcohol Dependence, 148, 85–92. https://doi.org/10.1016/j.drugalcdep.2014.12.025
   PubMed Web of Science ®Google Scholar
• Buckley, P. F., & Brown, E. S. (2006). Prevalence and consequences of dual diagnosis. The Journal of Clinical Psychiatry, 67(7), e01. https://doi.org/10.4088/jcp.0706e01
   PubMedGoogle Scholar
• Burleson, J. A., & Kaminer, Y. (2005). Self-efficacy as a predictor of treatment outcome in adolescent substance use disorders. Addictive Behaviors, 30(9), 1751–1764. https://doi.org/10.1016/j.addbeh.2005.07.006
   PubMed Web of Science ®Google Scholar
• Cho, H., & Witte, K. (2005). Managing fear in public health campaigns: A theory-based formative evaluation process. Health Promotion Practice, 6(4), 482–490. https://doi.org/10.1177/1524839904263912
   PubMedGoogle Scholar
• Collaborative, H. C. C. (2014). The Extended Parallel Process Model: An HC3 Research Primer. http://www.healthcommcapacity.org/wp-content/uploads/2014/09/Extended-Parallel-Processing-Model.pdf
   Google Scholar
• Dillard, J. P., Li, R., Meczkowski, E., Yang, C., & Shen, L. (2017). Fear responses to threat appeals: Functional form, methodological considerations, and correspondence between static and dynamic data. Communication Research, 44(7), 997–1018. https://doi.org/10.1177/0093650216631097
   Web of Science ®Google Scholar
• Dubé, E., Vivion, M., & MacDonald, N. E. (2015). Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: Influence, impact and implications. Expert Review of Vaccines, 14(1), 99–117. https://doi.org/10.1586/14760584.2015.964212
   PubMed Web of Science ®Google Scholar
• Edlund, M. J., Booth, B. M., & Feldman, Z. L. (2009). Perceived need for treatment for alcohol use disorders: Results from two national surveys. Psychiatric Services (Washington, D.C.), 60(12), 1618–1628. https://doi.org/10.1176/ps.2009.60.12.1618
   PubMed Web of Science ®Google Scholar
• Florence, C. S., Zhou, C., Luo, F., & Xu, L. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care, 54(10), 901–906. https://doi.org/10.1097/MLR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Friedmann, P. D., Wilson, D., Nunes, E. V., Hoskinson, R., Lee, J. D., Gordon, M., Murphy, S. M., Bonnie, R. J., Chen, D. T., Boney, T. Y., & O’Brien, C. P. (2018). Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? Journal of Substance Abuse Treatment, 85, 61–65. https://doi.org/10.1016/j.jsat.2017.01.018
   PubMed Web of Science ®Google Scholar
• Friesen, E. L., & Kurdyak, P. (2020). The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug and Alcohol Dependence, 216, 108244. https://doi.org/10.1016/j.drugalcdep.2020.108244
   PubMed Web of Science ®Google Scholar
• Hopwood, C. J., Good, E. W., & Morey, L. C. (2018). Validity of the DSM-5 levels of personality functioning scale-self report. Journal of Personality Assessment, 100(6), 650–659. https://doi.org/10.1080/00223891.2017.1420660
   PubMed Web of Science ®Google Scholar
• Jones, E. B. (2018). Medication-assisted opioid treatment prescribers in federally qualified health centers: Capacity lags in rural areas. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 34(1), 14–22. https://doi.org/10.1111/jrh.12260
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Quinn, E. K., Chaisson, C. E., Ciemins, E., Stempniewicz, N., White, L. F., & Larochelle, M. R. (2022). Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder. Journal of Substance Abuse Treatment, 133, 108540. https://doi.org/10.1016/j.jsat.2021.108540
   PubMed Web of Science ®Google Scholar
• Novak, P., Feder, K. A., Ali, M. M., & Chen, J. (2019). Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey. Journal of Substance Abuse Treatment, 98, 47–52. https://doi.org/10.1016/j.jsat.2018.12.006
   PubMed Web of Science ®Google Scholar
• Parker, M. H., & Tobin, B. (2001). Refusal of treatment. The Medical Journal of Australia, 174(10), 531–532. https://doi.org/10.5694/j.1326-5377.2001.tb143410.x
   PubMed Web of Science ®Google Scholar
• Priester, M. A., Browne, T., Iachini, A., Clone, S., DeHart, D., & Seay, K. D. (2016). Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: An integrative literature review. Journal of Substance Abuse Treatment, 61, 47–59. https://doi.org/10.1016/j.jsat.2015.09.006
   PubMed Web of Science ®Google Scholar
• Prochaska, J. O. (2008). Decision making in the transtheoretical model of behavior change. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 28(6), 845–849. https://doi.org/10.1177/0272989x08327068
   PubMed Web of Science ®Google Scholar
• Rapp, R. C., Xu, J., Carr, C. A., Lane, D. T., Wang, J., & Carlson, R. (2006). Treatment barriers identified by substance abusers assessed at a centralized intake unit. Journal of Substance Abuse Treatment, 30(3), 227–235. https://doi.org/10.1016/j.jsat.2006.01.002
   PubMed Web of Science ®Google Scholar
• Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (London, England), 373(9682), 2223–2233. https://doi.org/10.1016/S0140-6736(09)60746-7
   PubMed Web of Science ®Google Scholar
• Roberto, A. J., Mongeau, P. A., & Liu, Y. (2018). A (Re)defining moment for fear appeals: A comment on Kok et al. (2018). Health Psychology Review, 12(2), 144–146. https://doi.org/10.1080/17437199.2018.1445546
   PubMed Web of Science ®Google Scholar
• Roberto, A. J., Mongeau, P. A., Liu, Y., & Hashi, E. C. (2019). “Fear the flu, not the flu shot”: A test of the extended parallel process model. Journal of Health Communication, 24(11), 829–836. https://doi.org/10.1080/10810730.2019.1673520
   PubMed Web of Science ®Google Scholar
• Rounds-Bryant, J. L., Flynn, P. M., & Craighead, L. W. (1997). Relationship between self-efficacy perceptions and in-treatment drug use among regular cocaine users. The American Journal of Drug and Alcohol Abuse, 23(3), 383–395. https://doi.org/10.3109/00952999709016884
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramirez, D. C., Franklin, R. C., & Voaklander, D. (2018). Perceptions about alcohol harm and alcohol-control strategies among people with high risk of alcohol consumption in Alberta, Canada and Queensland, Australia. Journal of Preventive Medicine and Public Health = Yebang Uihakhoe Chi, 51(1), 41–50. https://doi.org/10.3961/jpmph.17.112
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. (2015a, September 28 2015). Medication and Counseling Treatment. Retrieved October 2 from https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2015b). Medication for the treatment of alcohol use disorder: A brief guide. In National Institute on Alcohol Abuse and Alcoholism. (Ed.).
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2015c, September 28). 2015 Methadone. Retrieved October 2 from https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2016a). Buprenorphine. Retrieved 26 September from https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2016b). September 12 2016 Naltrexone. Retrieved October 2 from https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2018). Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. In.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020). Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. In. United States Department of Health and Human Services.
   Google Scholar
• Thornton, J. D., Lyvers, E., Scott, V. G., & Dwibedi, N. (2017). Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia. Journal of the American Pharmacists Association: JAPhA, 57(2S), S12–S18.e4. e14. https://doi.org/10.1016/j.japh.2016.12.070
   PubMedGoogle Scholar
• United States Census Bureau. (2018). American Community Survey [Census].
   Google Scholar
• United States Department of Health and Human Services. (2017). October 26, HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html
   Google Scholar
• Wall, R., Rehm, J., Fischer, B., Brands, B., Gliksman, L., Stewart, J., Medved, W., & Blake, J. (2000). Social costs of untreated opioid dependence. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 77(4), 688–722. https://doi.org/10.1007/BF02344032
   PubMed Web of Science ®Google Scholar
• Wilson, H. D., Dansie, E. J., Kim, M. S., Moskovitz, B. L., Chow, W., & Turk, D. C. (2013). Clinicians’ attitudes and beliefs about opioids survey (CAOS): Instrument development and results of a national physician survey. The Journal of Pain, 14(6), 613–627. https://doi.org/10.1016/j.jpain.2013.01.769
   PubMed Web of Science ®Google Scholar
• Witkiewitz, K., Votaw, V. R., Vowles, K. E., & Kranzler, H. R. (2018). Opioid misuse as a predictor of alcohol treatment outcomes in the COMBINE study: Mediation by medication adherence. Alcoholism, Clinical and Experimental Research, 42(7), 1249–1259. https://doi.org/10.1111/acer.13772
   PubMed Web of Science ®Google Scholar
• Witkiewitz, K., & Vowles, K. E. (2018). Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: A critical review. Alcoholism, Clinical and Experimental Research, 42(3), 478–488. https://doi.org/10.1111/acer.13594
   PubMed Web of Science ®Google Scholar
• Witte, K. (1992). Putting the fear back into fear appeals: The extended parallel process model. Communication Monographs, 59(4), 329–349. https://doi.org/10.1080/03637759209376276
   Web of Science ®Google Scholar
• Witte, K., Cameron, K. A., McKeon, J. K., & Berkowitz, J. M. (1996). Predicting risk behaviors: Development and validation of a diagnostic scale. Journal of Health Communication, 1(4), 317–341. https://doi.org/10.1080/108107396127988
   PubMedGoogle Scholar
• Wombacher, K., Harrington, N. G., Scott, A. M., Helme, D. W., & Martin, C. (2019). Communication apprehension mediates the effects of past experience discussing substance use on child and adolescent psychiatrists’ self-efficacy. Patient Education and Counseling, 102(4), 651–655. https://doi.org/10.1016/j.pec.2018.10.020
   PubMed Web of Science ®Google Scholar
• Wu, L.-T., Zhu, H., & Swartz, M. S. (2016). Treatment utilization among persons with opioid use disorder in the United States. Drug and Alcohol Dependence, 169, 117–127. https://doi.org/10.1016/j.drugalcdep.2016.10.015
   PubMed Web of Science ®Google Scholar